Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002.
Ischaemic stroke is the only neurological manifestation accepted as a clinical diagnostic criterion for the antiphospholipid syndrome (APS). This association is reasonably well established in patients first diagnosed with APS but is less clear in randomly selected stroke patients who test positive on one occasion for antiphospholipid antibodies and who have no other evidence of systemic autoimmune disease. We propose a grading system that posits stroke to be definitely, likely or possibly associated with antiphospholipid antibodies (aPL). Further, there are limited prospective data to determine appropriate treatment. There is controversy as to whether the presence of aPL even increases risk of a recurrent stroke or other thromboembolic event, although data point to persistent medium-high titre aCL and/or LA as risk factors for recurrence. In the absence of data to guide clinicians on the best treatment, we cannot make strong recommnendations as to optimal therapy, nor can we propose clear consensus treatment guidelines.
Brey
R L
RL
Department of Medicine, Division of Neurology, University of Texas Health Science Center-San Antonio, Texas 78229-3900, USA. brey@uthscsa.edu
Chapman
J
J
Levine
S R
SR
Ruiz-Irastorza
G
G
Derksen
R H W M
RH
Khamashta
M
M
Shoenfeld
Y
Y
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage; D016736:Antiphospholipid Syndrome / Q000150:complications*; D006801:Humans; D012307:Risk Factors; D020521:Stroke / Q000276:immunology* / Q000517:prevention & control*
D000925:Anticoagulants